导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.05% | 3205/4773 |
| 近一周 | -2.57% | 2574/5462 |
| 近一月 | -3.49% | 1783/5421 |
| 近一季 | -10.21% | 3430/5209 |
| 近半年 | -10.93% | 3691/4920 |
| 近一年 | 2.03% | 2209/4366 |
| 近两年 | 71.93% | 942/2954 |
| 近三年 | 33.02% | 933/2253 |
| 成立以来 | 120.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.18% 1613/4961 |
11.21% 2361/5312 |
- - |
- - |
| 2025 | 35.21% 999/4813 |
7.00% 541/3635 |
5.18% 640/4076 |
16.22% 2694/4524 |
3.38% 687/4813 |
| 2024 | 5.30% 1842/3463 |
-8.47% 2230/2808 |
-5.88% 1814/3014 |
14.31% 2008/3129 |
6.93% 472/3463 |
| 2023 | -1.49% 517/2656 |
9.18% 423/2280 |
-2.65% 625/2385 |
-4.57% 1162/2515 |
-2.89% 550/2655 |
| 2022 | -16.43% 480/2207 |
-15.20% 1027/1919 |
10.26% 265/2016 |
-10.62% 433/2113 |
- 1550/2208 |
| 2021 | 25.20% 112/1822 |
-2.27% 612/1255 |
13.03% 298/1330 |
5.01% 303/1466 |
7.93% 171/1822 |
| 2020 | 38.28% 364/1250 |
-1.07% 201/1028 |
21.01% 252/1067 |
9.80% 619/1164 |
5.20% 798/1184 |
| 2019 | 35.76% 370/1092 |
32.91% 154/739 |
-5.41% 464/788 |
0.59% 506/850 |
7.36% 443/918 |
| 2018 | -23.76% 299/834 |
- - |
-12.90% 417/631 |
-5.89% 386/660 |
-7.27% 62/682 |
| 2017 | -1.34% 496/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 创金合信中证1000指数增强C VS. 长安沪深300非周期A(740101) |